Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
Authors:
- Ami CitriACAmi Citri
- Jorma IsolaJIJorma Isola
- Yosef YardenYYYosef Yarden
- János SzöllősiJSJános Szöllősi
- György VerebGVGyörgy Vereb
- 1 April 2006
- journal article
- Published by Elsevier in Immunology Letters
- Vol. 104 (1-2) , 146-155
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopyCytometry Part A, 2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complexNature Structural & Molecular Biology, 2005
- Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and GeldanamycinMolecular Biology of the Cell, 2004
- Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transductionNature Biotechnology, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing FunctionBiochemical and Biophysical Research Communications, 2001
- Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersThe EMBO Journal, 1998
- Neu Differentiation Factor Inhibits EGF BindingJournal of Biological Chemistry, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987